Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
14 06 2021
14 06 2021
Historique:
entrez:
15
6
2021
pubmed:
16
6
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
A comprehensive genomic characterization of a large, high-quality cohort of upper tract urothelial carcinomas (UTUCs) in this issue of Cancer Cell reveals that UTUCs can be divided into five DNA-based molecular subtypes. Feasibility data establish that molecular subtyping can be performed non-invasively by sequencing tumor DNA in urine.
Identifiants
pubmed: 34129819
pii: S1535-6108(21)00270-1
doi: 10.1016/j.ccell.2021.05.004
pii:
doi:
Substances chimiques
DNA, Neoplasm
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
745-747Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests David McConkey: Janssen, H3 Biomedicine (paid consulting); Astra-Zeneca (research support). Jean Hoffman-Censits: Seattle Genetics, Astra-Zeneca, Genentech, Foundation Medicine (paid consulting); Foundation Medicine (non-financial research support). Philip Pierorazio: Urogen Pharmaceuticals (paid consulting, scientific advisory board, site PI). Andres Matoso: Caris Diagnostics (paid consulting); PATHAI (partner/contractor). Nirmish Singla and Kara Lombardo declare no competing interests.